Ngā hua rapu - Vivek Rathi
- E whakaatu ana i te 1 - 3 hua o te 3
-
1
-
2
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma mā Sarah A. Best, Sheryl Ding, Ariena Kersbergen, Xueyi Dong, Ji‐Ying Song, Yi Xie, Boris Reljić, Kaiming Li, James E. Vince, Vivek Rathi, Gavin Wright, Matthew E. Ritchie, Kate D. Sutherland
I whakaputaina 2019Artigo -
3
Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment mā Sarah A. Best, David P. De Souza, Ariena Kersbergen, Antonia N. Policheni, Saravanan Dayalan, Dedreia Tull, Vivek Rathi, Daniel H.D. Gray, Matthew E. Ritchie, Malcolm J. McConville, Kate D. Sutherland
I whakaputaina 2018Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Biology
Gene
Genetics
Lung cancer
Medicine
Oncology
Cancer
Cancer research
KEAP1
Transcription factor
Adenocarcinoma
Cell biology
Cohort
DNA sequencing
Disease
Histopathology
Immune system
Immunology
Internal medicine
KRAS
Lung
Mutant
Mutation
PI3K/AKT/mTOR pathway
Pathology
Signal transduction
Tumor microenvironment